Taylor Leavitt is the President of Leavitt Equity Partners, an affiliated value-add private equity firm with two funds investing over $230 million in capital. Leavitt Equity Partners (LEP) seeks to invest capital into growth and lower mid-market opportunities that align with the firm’s core beliefs about the future of health care. Taylor manages and executes the investment activities and subsequent performance, including directing the firm’s investment decisions, portfolio holdings, due diligence processes, and relationships with its investors and partner funds. Taylor also serves as a board member (or observer) on several portfolio companies as well as a board member of Leavitt Partners, LLC.
Prior to forming Leavitt Equity Partners, Taylor led the Leavitt Partners Equity Practice, which directed and managed Leavitt Partners’ portfolio holdings, due diligence processes, and relationships with other private equity funds and financial institutions. Taylor continues to manage Leavitt Partners’ internal equity portfolio.
Prior to joining Leavitt Partners in 2009, Taylor worked for ZARS Pharma, a venture capital-funded pharmaceutical company engaged in corporate licensing and business development operations. While at ZARS, Taylor identified, negotiated, and executed strategic corporate transactions on a global basis, including mergers and acquisitions, national and international product licenses, IP and technology licenses, and research and development alliances. Before ZARS, Taylor was a founding employee for the Park City Center for Public Policy. In other capacities, Taylor has worked with Epic Venture Capital, SAIC, and Keystone Global Investment LLC.
Taylor received his master’s degree in business administration from the UCLA Anderson School of Business with an emphasis in private equity and entrepreneurship. He graduated magna cum laude from Utah State University studying finance, economics, and international business.